Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Heidelberg Pharma AGXTER:HPHA -1.92%32 Days Payable is 1,161.88 as of May. 2026, which is 457% above its 10-year median of 208.54. GuruFocus rates XTER:HPHA with a GF Score™ of 32/100 and a GF Value™ of €0.96 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 701 Biotechnology companies, Heidelberg Pharma AG ranks better than 92.3% on this metric.
The historical rank and industry rank for Heidelberg Pharma AG's Days Payable or its related term are showing as below:
XTER:HPHA'
s Days Payable Range Over the Past 10 Years
Min: 69.18 Med: 208.54 Max: 8529.86
Current: 3293.84
During the past 13 years, Heidelberg Pharma AG's highest Days Payable was 8529.86. The lowest was 69.18. And the median was 208.54.
XTER:HPHA's Days Payable is ranked better than 92.3% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs XTER:HPHA: 3293.84
Heidelberg Pharma AG's Days Payable
declined
from May. 2025 (8,054.57) to May. 2026 (1,161.88).
It may suggest that Heidelberg Pharma AGaccelerated paying its suppliers.
Heidelberg Pharma AG Days Payable Related Terms
Heidelberg Pharma AG Days Payable Historical Data
* Premium members only.
The historical data trend for Heidelberg Pharma AG's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:HPHA vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Heidelberg Pharma AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Heidelberg Pharma AG Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Days Payable distribution charts can be found below:
* The bar in red indicates where Heidelberg Pharma AG's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Heidelberg Pharma AG's Days Payable for the fiscal year that ended in Nov. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Heidelberg Pharma AG (XTER:HPHA) has a Days Payable of 1,161.88 as of May. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Heidelberg Pharma AG and its competitors. This is 457% above median its historical median of 208.54. Over the past decade, Heidelberg Pharma AG's Days Payable has ranged from 69.18 to 8,529.86. According to the industry distribution chart, Heidelberg Pharma AG ranks #54 out of 701 companies in the Biotechnology industry, placing it in the top 7.7%.
Is Heidelberg Pharma AG's Days Payable too high?
Heidelberg Pharma AG's current Days Payable of 1,161.88 is 457% above median its 10-year median of 208.54. Over the past 10 years, this metric has ranged from a low of 69.18 to a high of 8,529.86. The Biotechnology industry median Days Payable is 112.84. Heidelberg Pharma AG's value of 1,161.88 is 929.7% above this industry median. Based on the distribution chart, Heidelberg Pharma AG ranks #54 out of 701 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Heidelberg Pharma AG has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Heidelberg Pharma AG ranks #54 out of 701 companies for Days Payable. This places Heidelberg Pharma AG in the top 8% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.84. Heidelberg Pharma AG's value of 1,161.88 is 929.7% above this benchmark. Historically, Heidelberg Pharma AG's own Days Payable has ranged from 69.18 to 8,529.86 over the past decade. While the company's 10-year median is 208.54 vs. the industry median of 112.84, Heidelberg Pharma AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Heidelberg Pharma AG's current Days Payable of 1,161.88 is 929.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Heidelberg Pharma AG and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Heidelberg Pharma AG's current Days Payable is 1,161.88, which is 457% above median its own 10-year median of 208.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (XTER:HPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.96, compared to a current price of €2.55 — trading 165.6% above its estimated fair value. The current Days Payable is 1,161.88, which is 457% above median its 10-year median of 208.54 and 929.7% above the Biotechnology industry median of 112.84. Heidelberg Pharma AG's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Heidelberg Pharma AG (XTER:HPHA), the current Days Payable is 1,161.88 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Heidelberg Pharma AG (XTER:HPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be overvalued.
The current stock price of €2.55 is trading 165.6% above its estimated GF Value™ of €0.96.
GuruFocus considers Heidelberg Pharma AG to be Significantly Overvalued.
Key valuation signals for XTER:HPHA:
Days Payable: 1,161.88 (457% above median its 10-year median of 208.54)
GF Value™: €0.96 vs. price of €2.55 (165.6% above fair value)
Industry Position: 929.7% above the Biotechnology median (#54 of 701)
No single metric tells the full story. See the XTER:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
32GF Score
Get the complete analysis for XTER:HPHA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:HPHA has been successfully added to your 
